Poniard Pharmaceuticals Reports Q4 EPS $(0.11)

Poniard Pharmaceuticals, Inc. PARD today reported financial results for the fourth quarter. The Company reported a net loss of $5.2 million ($0.11 diluted loss per share on a loss applicable to common shares of $5.2 million) for the quarter ended December 31, 2010, compared with a net loss of $13.2 million ($0.36 diluted loss per share on a loss applicable to common shares of $13.3 million) for the quarter ended December 31, 2009.